Delayed emesis

a dilemma in antiemetic control

Rebecca A. Clark, Richard J. Gralla

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Delayed emesis remains a major factor limiting successful antiemetic treatment. It is well described in patients receiving cisplatin at doses of 100 mg/m2 or greater (occurring in nearly 90% of patients), but its incidence and severity in other settings is less well known. Several studies have indicated that combinations of oral metoclopramide plus dexamethasone can decrease the incidence of this problem by one-half; however, a large number of patients remain for whom delayed emesis is their main emetic problem. To date, studies with single-agent serotonin antagonists have not shown encouraging efficacy. In addition, it appears that delayed emesis may begin as early as 16 h after chemotherapy, yielding implications for new study designs. Proper methodology for clinical studies has been demonstrated in a few well-conducted trials, which should form a basis for future research.

Original languageEnglish (US)
Pages (from-to)182-185
Number of pages4
JournalSupportive Care in Cancer
Volume1
Issue number4
DOIs
StatePublished - Jul 1993
Externally publishedYes

Fingerprint

Antiemetics
Vomiting
Emetics
Serotonin Antagonists
Metoclopramide
Incidence
Dexamethasone
Cisplatin
Drug Therapy
Therapeutics

Keywords

  • Antiemetics
  • Cisplatin
  • Delayed emesis
  • Methodology
  • Metoclopramide
  • Serotonin antagonists

ASJC Scopus subject areas

  • Nursing(all)
  • Oncology

Cite this

Delayed emesis : a dilemma in antiemetic control. / Clark, Rebecca A.; Gralla, Richard J.

In: Supportive Care in Cancer, Vol. 1, No. 4, 07.1993, p. 182-185.

Research output: Contribution to journalArticle

@article{25c096afe382491d8e2e1ec3159a9c05,
title = "Delayed emesis: a dilemma in antiemetic control",
abstract = "Delayed emesis remains a major factor limiting successful antiemetic treatment. It is well described in patients receiving cisplatin at doses of 100 mg/m2 or greater (occurring in nearly 90{\%} of patients), but its incidence and severity in other settings is less well known. Several studies have indicated that combinations of oral metoclopramide plus dexamethasone can decrease the incidence of this problem by one-half; however, a large number of patients remain for whom delayed emesis is their main emetic problem. To date, studies with single-agent serotonin antagonists have not shown encouraging efficacy. In addition, it appears that delayed emesis may begin as early as 16 h after chemotherapy, yielding implications for new study designs. Proper methodology for clinical studies has been demonstrated in a few well-conducted trials, which should form a basis for future research.",
keywords = "Antiemetics, Cisplatin, Delayed emesis, Methodology, Metoclopramide, Serotonin antagonists",
author = "Clark, {Rebecca A.} and Gralla, {Richard J.}",
year = "1993",
month = "7",
doi = "10.1007/BF00366444",
language = "English (US)",
volume = "1",
pages = "182--185",
journal = "Supportive Care in Cancer",
issn = "0941-4355",
publisher = "Springer Verlag",
number = "4",

}

TY - JOUR

T1 - Delayed emesis

T2 - a dilemma in antiemetic control

AU - Clark, Rebecca A.

AU - Gralla, Richard J.

PY - 1993/7

Y1 - 1993/7

N2 - Delayed emesis remains a major factor limiting successful antiemetic treatment. It is well described in patients receiving cisplatin at doses of 100 mg/m2 or greater (occurring in nearly 90% of patients), but its incidence and severity in other settings is less well known. Several studies have indicated that combinations of oral metoclopramide plus dexamethasone can decrease the incidence of this problem by one-half; however, a large number of patients remain for whom delayed emesis is their main emetic problem. To date, studies with single-agent serotonin antagonists have not shown encouraging efficacy. In addition, it appears that delayed emesis may begin as early as 16 h after chemotherapy, yielding implications for new study designs. Proper methodology for clinical studies has been demonstrated in a few well-conducted trials, which should form a basis for future research.

AB - Delayed emesis remains a major factor limiting successful antiemetic treatment. It is well described in patients receiving cisplatin at doses of 100 mg/m2 or greater (occurring in nearly 90% of patients), but its incidence and severity in other settings is less well known. Several studies have indicated that combinations of oral metoclopramide plus dexamethasone can decrease the incidence of this problem by one-half; however, a large number of patients remain for whom delayed emesis is their main emetic problem. To date, studies with single-agent serotonin antagonists have not shown encouraging efficacy. In addition, it appears that delayed emesis may begin as early as 16 h after chemotherapy, yielding implications for new study designs. Proper methodology for clinical studies has been demonstrated in a few well-conducted trials, which should form a basis for future research.

KW - Antiemetics

KW - Cisplatin

KW - Delayed emesis

KW - Methodology

KW - Metoclopramide

KW - Serotonin antagonists

UR - http://www.scopus.com/inward/record.url?scp=0027633837&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027633837&partnerID=8YFLogxK

U2 - 10.1007/BF00366444

DO - 10.1007/BF00366444

M3 - Article

VL - 1

SP - 182

EP - 185

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

SN - 0941-4355

IS - 4

ER -